CUDC-907 Phase 1 and Phase 2 (Interim) Trial Results
Curis Reports Second Quarter 2017 Financial Results
August 03, 2017 07:00 ET | Curis, Inc
LEXINGTON, Mass., Aug. 03, 2017 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates...
Curis to Release Sec
Curis to Release Second Quarter 2017 Financial Results and Hold Conference Call on August 3, 2017
July 26, 2017 07:00 ET | Curis, Inc
LEXINGTON, Mass., July 26, 2017 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the...
Curis Reports Induce
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
July 05, 2017 16:30 ET | Curis, Inc
LEXINGTON, Mass., July 05, 2017 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates...
UPDATE - Curis to Pr
UPDATE - Curis to Present at the Jefferies Healthcare Conference
June 01, 2017 12:07 ET | Curis, Inc
LEXINGTON, Mass., June 01, 2017 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics...
Curis to Present at
Curis to Present at the Jefferies Healthcare Conference
June 01, 2017 07:00 ET | Curis, Inc
LEXINGTON, Mass., June 01, 2017 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for...
Curis Announces Pres
Curis Announces Presentations Related to CA-170 and CUDC-907 at 2017 ASCO Annual Meeting
May 25, 2017 07:00 ET | Curis, Inc
LEXINGTON, Mass., May 25, 2017 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for...
Curis Reports First
Curis Reports First Quarter 2017 Financial Results
May 04, 2017 07:00 ET | Curis, Inc
LEXINGTON, Mass., May 04, 2017 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates for...
Curis to Release Fir
Curis to Release First Quarter 2017 Financial Results and Hold Conference Call on May 4, 2017
April 28, 2017 14:04 ET | Curis, Inc
LEXINGTON, Mass., April 28, 2017 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the...
Curis Reports Induce
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
April 05, 2017 07:00 ET | Curis, Inc
LEXINGTON, Mass., April 05, 2017 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates...
Curis to Present Pre
Curis to Present Preclinical Data on IRAK4 Kinase Inhibitor CA-4948 at AACR Annual Meeting
March 30, 2017 13:30 ET | Curis, Inc
LEXINGTON, Mass., March 30, 2017 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates...